Uncategorized
DRCR.net Protocol T: At 2 years, Eylea, Avastin, Lucentis all reduce need for injections, improve visual acuity
Two-year results of the Diabetic Retinopathy Clinical Research Network Protocol T study show that about half the number of anti-VEGF injections needed to treat diabetic macular edema in the first year of the study were needed in the second year, regardless of which study agent was used. The randomized clinical trial included 660 patients with visual acuity impairment from DME. Patients were randomized to receive intravitreal injections of 2 mg of Eylea (aflibercept, Regeneron), 1.25 mg of compounded Avastin (bevacizumab, Genentech) or 0.3 mg of Lucentis (ranibizumab, Genentech). Visual acuity (Read more...)